We already know what the announcement will be at the AD/PD conference: That mouse studies show that PBT2 helps reduce tau tangles. Ergo the big and very brief spike yesterday. These pre-clinical announcements have a hit-and-miss effect on the share price. Sometimes the price pops for a day or two. Sometimes it hardly budges.
Just hang onto your shares until at least October, when we'll hear the results for the HD study. Add more shares now that the price is back down to the $2 ballpark if you feel so inclined.
JMHO,but seems like MM's always do that.That's one of the reason I usually buy later in the day.That way if they try to shake out the longs I am buying close to the low.
Always do your own due diligence.
Best of luck to longs...
I just took advantage of the dip and increased my holdings by 40% at $2.35. That is a pretty good price. I think anything in this price range is a gift if the drug works. All indications so far are that the drug is working. I also like the fact that they have a discovery platform with many molecules in their library of potential candidates for addressing huge unmet needs/markets with their unique/novel approach (mechanism of action). Let's hope for the patient's sake and our financial well being their drugs prove to be the solution. Good luck to all!